Showing 900 results for "sarcoidosis"

The power of purple during Sarcoidosis Awareness Month

“Sarc-a-what?” That’s usually the response we get when we tell someone we have sarcoidosis. “What’s that?” they ask, and then tune out the long explanation we begin to give. “Oh, good,” they add, “at least it’s not cancer.” And that’s precisely why we need Sarcoidosis Awareness Month. Throughout…

This Sarcoidosis Awareness Month ‘Stand Up for Sarc’

The Foundation for Sarcoidosis Research (FSR) is offering ways to participate in National Sarcoidosis Awareness Month, observed each April, to call attention to sarcoidosis and the 175,000 U.S. residents thought to be living with the disease. Despite advances in research, sarcoidosis remains challenging to diagnose and…

FSR’s Inaugural Sarcoidosis Crystal Awards Gala set for May 24

Four sarcoidosis patients and researchers who work to better understand the disease and raise awareness about it will be honored at the Foundation for Sarcoidosis Research (FSR)’s Inaugural Sarcoidosis Crystal Awards Gala  Celebrating Connections, Collaboration, and Catalyzing Research. The gala, which will take place May 24 from 6…

Trial tests app that targets fatigue in sarcoidosis

A clinical trial is testing whether a smartphone app called SPARC, which prompts users to perform meditative breathing exercises and contains disease-relevant education modules, can help ease fatigue and improve life quality for people with sarcoidosis. The study (NCT05230693), sponsored by the Medical University of South Carolina, is…

RV Damage on MRI Linked to Heart Events in Cardiac Sarcoidosis

Findings of defects in the heart’s right ventricle, as assessed with an MRI scan, can predict the occurrence of cardiovascular events in people with confirmed or suspected cardiac sarcoidosis, a review study showed. Particularly, scarring in the right ventricle muscle was a “strong independent predictor” of sudden heart-related death,…

Efzofitimod Earns Orphan Drug Status for Sarcoidosis in Europe

The European Commission (EC) has granted orphan drug designation to aTyr Pharma’s lead therapeutic candidate efzofitimod for treating sarcoidosis. Orphan drug status is granted to investigational therapies that show significant potential for treating chronic or life-threatening disease that affect no more than five in 10,000 people in the…